Le Lézard
Classified in: Health
Subject: FDA

Innoblative's SIRAtm RFA Electrosurgical Device Receives FDA Clearance

CHICAGO, April 9, 2019 /PRNewswire/ -- Innoblative Designs, Inc. (Innoblative), a private medical device company committed to developing next generation, advanced-energy surgical solutions, announced it received U.S. Food and Drug Administration (FDA) clearance for its SIRAtm RFA Electrosurgical Device, a novel radiofrequency ablation (RFA) applicator that supplies energy for use in electrosurgery, specifically for intraoperative coagulation and ablation of soft tissue.

"The design of the SIRA applicator makes it uniquely suited to ablate large surface areas," said Dr. Brendan Visser, Associate Professor of Surgery at Stanford University School of Medicine. "The large spherical applicator minimizes subjective repositioning of the device, leading to a more controllable and predictable ablation performance. A device like this hasn't existed before, and I'm excited to see this advancement in the operating room helping patients."

Radiofrequency ablation of soft tissue has been shown in multiple long-term clinical studies to reduce complications and reoperations.1 However, current conventional RF applicators are not optimized to treat large surface areas, which can lead to long procedure times and variable ablation depths. Innoblative's SIRA device is used in conjunction with a radiofrequency electrosurgical generator to coagulate and ablate large surface areas in open abdominal surgical procedures with minimal need for repositioning. The unique shape of the SIRA applicator circumferentially delivers RF energy, yielding reproducible ablation depths.

"The SIRA device breaks the usual convention of currently available RFA and microwave offerings," stated Dr. Andrei Stieber, General Surgeon at DeKalb Surgical Associates and Northside Hospital in Atlanta, Georgia. "For surface lesions, SIRA offers an easy to use, intuitive and controllable solution for a common problem in abdominal surgery. I believe the SIRA device adds an important tool to the surgeon's armamentarium."

"Receiving FDA clearance is a significant milestone for Innoblative, and we look forward to commercializing the SIRA device in the US market," said Tyler R. Wanke, CEO and Co-founder of Innoblative. "With our initial indication in hand, we continue working towards obtaining additional indications where our novel technology can significantly impact patient care."

The global market size for ablation procedures is estimated at approximately $15 billion USD and is expected to grow at a CAGR of 13%.2 The increase in prevalence of cancer is a major factor contributing to this market growth. Based on statistics published by the World Health Organization (WHO), 13% of the global population suffers from cancer and it is expected to rise by approximately 70% over the next few decades.3

About Innoblative Designs, Inc.

Innoblative Designs Inc. is a medical device company whose mission is to develop next generation, advanced-energy surgical solutions that improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. For more information, visit Innoblative.com.

Media Contact:
Katie Arnold
Sprig Consulting

1Data on file at Innoblative Designs, Inc.

2Melvin Bright. Jan. 2018. Global Ablation Devices Market ? Trends, Insights & Forecasts, Strategic assessment of a high growth market.

3Grand View Research Market Report. Nov. 2018.  Tumor Ablation Market Size, Share & Trends Analysis Report by Treatment (Surgical, Percutaneous), By Application (Lung, Liver Cancer), By Technology (Radiofrequency, Microwave), And Segment Forecasts, 2018 ? 2025. https://www.grandviewresearch.com/industry-analysis/tumor-ablation-market


These press releases may also interest you

at 05:05
Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis' measles...

at 05:00
The global ophthalmic drugs market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The market is estimated at $25bn in 2018, dominated by the retinal disorder drugs segment. How this report will benefit youRead on to...

at 04:45
As per a latest report on global Human Growth Hormone Market by Transparency Market Research, the market is expected to witness a substantial growth in coming years. The report predicts that the growth of the market is attributed to rising cases of...

at 04:10
c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully expanded its product business in the first half of 2019. Besides sales increases across the entire portfolio,...

at 04:00
Southern Illinois University Edwardsville is introducing a Master of Science degree in nutrition and dietetics designed for students who desire a master's, while gaining eligibility to become a registered dietitian and pursue careers as entry level...

at 03:35
FoodMarble, the Irish-based digital health company, has received clinical validation from a leading international digestive health research group. The start-up, which was founded in 2016, has developed a breakthrough device, AIRE, to help people...

News published on 9 april 2019 at 09:00 and distributed by: